Are Sodium-Glucose Cotransporter-2 Inhibitors the Cherry on Top of Cardio-Oncology Care?
Cardiovascular Drugs and Therapy · 2025-08 · 39 (4) · 849-856
DOI: 10.1007/s10557-024-07604-x ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cardiovascular Drugs and Therapy, online erschienen am 03.07.2024. Verfasst von Carlos A Gongora und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Montefiore Medical Center at Albert Einstein School of Medicine, Bronx, NY, USA. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Neoplasms, Anthracyclines. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Abstract (Originalsprache)
The increasing aging of the population combined with improvements in cancer detection and care has significantly improved the survival and quality of life of cancer patients. These benefits are hampered by the increase of cardiovascular diseases being heart failure the most frequent manifestation of cardiotoxicity and becoming the major cause of morbidity and mortality among cancer survivor. Current strategies to prevent cardiotoxicity involves different approaches such as optimal management of CV risk factors, use of statins and/or neurohormonal medications, and, in some cases, even the use of chelating agents. As a class, SGLT2-i have revolutionized the therapeutic horizon of HF patients independently of their ejection fraction or glycemic status. There is an abundance of data from translational and observational clinical studies supporting a potential beneficial role of SGLT2-i in mitigating the cardiotoxic effects of cancer patients receiving anthracyclines. These findings underscore the need for more robust clinical trials to investigate the effect on cardiovascular outcomes of the prophylactic SGLT2-i treatment in patients undergoing cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Montefiore Medical Center at Albert Einstein School of Medicine, Bronx, NY, USA.
- Lee Health Heart Institute, Fort Myers, FL, USA.
- Cardiology Department, Instituto de Enfermedades Neoplásicas, Lima, Peru.
- Heart Failure Unit, University Hospital Fundacion Santa Fe, Universidad de los Andes, Bogota, Colombia.
- Hospital Juan Tanca Marengo, Guayaquil, Ecuador.
- Instituto Nacional de Cardiología "Ignacio Chávez", Mexico City, Mexico.
ORCID-Profile: Juan Badimon
Zitieren
APA
Gongora, C. A., Zhang, L., Mattei, J. L., Ruiz-Mori, E., Gonzalez-Robledo, G., Slipczuk, L., Lara, J., Cossio-Aranda, J. E., & Badimon, J. (2025). Are Sodium-Glucose Cotransporter-2 Inhibitors the Cherry on Top of Cardio-Oncology Care?. Cardiovascular Drugs and Therapy, 39(4), 849-856. https://doi.org/10.1007/s10557-024-07604-x
Vancouver
Gongora CA, Zhang L, Mattei JL, Ruiz-Mori E, Gonzalez-Robledo G, Slipczuk L, et al. Are Sodium-Glucose Cotransporter-2 Inhibitors the Cherry on Top of Cardio-Oncology Care?. Cardiovascular Drugs and Therapy. 2025;39(4):849-856. doi:10.1007/s10557-024-07604-x
BibTeX
@article{Gongora2025,
author = {Gongora, Carlos A and Zhang, Lili and Mattei, Juan Lopez and Ruiz-Mori, Enrique and Gonzalez-Robledo, Gina and Slipczuk, Leandro and Lara, Joffre and Cossio-Aranda, Jorge E and Badimon, Juan},
title = {Are Sodium-Glucose Cotransporter-2 Inhibitors the Cherry on Top of Cardio-Oncology Care?},
journal = {Cardiovascular Drugs and Therapy},
year = {2025},
volume = {39},
number = {4},
pages = {849--856},
doi = {10.1007/s10557-024-07604-x}
}
EUVIMED